Loading...
Market
What will be the next major milestone announcement for BioAge Labs' azelaprag by September 26, 2025?
2
Resolution / Starting Odds
Phase II trial results • 25%
Phase III trial initiation • 25%
New partnership announcement • 25%
Other • 25%
Official press releases from BioAge Labs or clinical trial updates
Story
BioAge Labs Raises $198M in Upsized IPO at $18 Midpoint for Obesity Drug Research
Sep 26, 2024, 03:40 AM
BioAge Labs, a weight-loss drug developer, has successfully raised $198 million through its upsized U.S. initial public offering (IPO), pricing its shares at the midpoint of $18 each. The company aims to use the funds to advance its anti-obesity drug research, particularly focusing on its muscle-building obesity drug candidate, azelaprag. The IPO was upsized again due to increased demand, reflecting investor confidence in BioAge Labs' pivot to obesity drug research.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
Initiate clinical trial • 25%
Secure additional funding • 25%
Enter partnership • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
Preclinical success • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%